January 1, 2006Toxicologic Pathology
Angiogenesis: Bench to Bedside, Have We Learned Anything?
Key result
Angiogenesis therapy for end-stage ischemic cardiomyopathy has failed to show benefit in phase II trials, highlighting the need for a structured model to overcome challenges like the placebo effect.
Population
End-stage ischemic cardiomyopathy patients refractory to other established therapies
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Angiogenesis therapy should not yet enter practice for end-stage ischemic cardiomyopathy; leaves open whether structured models can surmount phase II barriers.
Structured PICO
P
Population
End-stage ischemic cardiomyopathy patients refractory to other established therapies
I
Intervention
Angiogenesis therapy (single growth factor treatments)
This review highlights the translational challenges of angiogenesis therapy for ischemic cardiomyopathy and proposes a structured model for future research.
Limitations
- Complexity of angiogenesis process
- Challenges in creating animal models to replicate and study this process in ischemic adult human myocardium
- Failure to control for the powerful placebo effect in the clinical trials
- Inadequate methods of outcomes measures assessment
- Challenges in creating animal models to replicate ischemic adult human myocardium
- Failure to control for the powerful placebo effect in clinical trials
Cite This Study
Lee et al. (2006) conducted a review in End-stage ischemic cardiomyopathy. Angiogenesis therapy was evaluated. Angiogenesis therapy for end-stage ischemic cardiomyopathy has failed to show benefit in phase II trials, highlighting the need for a structured model to overcome challenges like the placebo effect.